Rahul K Thakur,Eunice S Wang
Rahul K Thakur
Pharmacologic targeting of the menin-KMT2A protein-protein interaction has emerged as a therapeutic breakthrough for acute leukemias harboring KMT2A rearrangements or NPM1 mutations. The first-in-class menin inhibitor (revumenib) achieved a...
Modern management of congenital thrombotic thrombocytopenic purpura (cTTP) [0.03%]
先天性血栓性血小板减少性紫癜(cTTP)的现代治疗方案
Alice Taylor,Marie Scully
Alice Taylor
Congenital thrombotic thrombocytopenic purpura (cTTP) arises from an inherited deficiency of ADAMTS13, causing a thrombotic microangiopathy with multisystemic sequelae. Acute cTTP relapse can cause arteriovascular thrombosis, and registry d...
Endless possibilities and how to exploit them? What is the optimal treatment sequence? [0.03%]
无尽的可能和如何利用它们？什么是最优治疗顺序？
Rajshekhar Chakraborty,Divaya Bhutani,Suzanne Lentzsch
Rajshekhar Chakraborty
The therapeutic landscape of multiple myeloma has undergone a profound transformation with the incorporation of anti-CD38 monoclonal antibody (mAb)-based quadruplet regimens in the frontline setting and T-cell redirecting immunotherapies in...
William J Powers
William J Powers
The term cryptogenic strokes refers to ischemic strokes that, after thorough evaluation, do not meet criteria for any of 4 designated major subtypes: stenosis due to large or medium artery atherosclerosis, cardiac pathology that could lead ...
Anticoagulation in malignancy: the patient who bleeds and clots simultaneously [0.03%]
肿瘤患者的抗凝治疗：出血和血栓的患者
Sargam Kapoor,Andrew M Peseski,Thomas L Ortel
Sargam Kapoor
Patients with active malignancy frequently require anticoagulation for a variety of indications, including thrombosis, atrial fibrillation, or mechanical heart valves. Cancer-associated thrombosis is associated with significant morbidity an...
Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment [0.03%]
儿科Langerhans细胞组织细胞增生症和Rosai-Dorfman病的诊断和治疗进展：治疗方法、生物标志物及疗效评估
Olive S Eckstein,Nitya Gulati
Olive S Eckstein
Histiocytic disorders are characterized by abnormal accumulation of myeloid-derived histiocytes and a shared biology marked by RAS/MAPK/ERK pathway activation, yet the rarity and heterogeneity of these conditions have limited the availabili...
Immune targeting in Ph-negative and Ph-positive B-ALL: improving outcomes and minimizing chemotherapy in adult B-ALL [0.03%]
Ph阴性和Ph阳性B-ALL的免疫治疗：改善预后和减少化疗在成人B-ALL中的应用
Kristen M O&#x;Dwyer
Kristen M O&#x;Dwyer
With the addition of antibody-based immunotherapy to frontline treatment regimens for B-lineage acute lymphoblastic leukemia (B-ALL), patients across the age spectrum now experience superior long-term survival. The pressing question for the...
Sanctuary sites and extramedullary relapses in the chemo-free world: insights from immunotherapies in B-ALL [0.03%]
无化疗时代的避难 sanctuary 症和中枢神经系统以外的复发：B 细胞急淋免疫治疗带来的启示
Ryan D Cassaday
Ryan D Cassaday
When acute lymphoblastic leukemia (ALL) involves extramedullary sites, the appropriate pathologic term for this is lymphoblastic lymphoma. The biological mechanisms underpinning this process are not clear, but they are presumed to involve a...
Posttransplant cells for the win? DLI and adoptive cell therapy to eradicate MRD [0.03%]
移植后的细胞能够胜出吗？用于清除微小残留病灶的DLI和过继性细胞疗法
Pleun Schonewille,Anna van Rhenen,Renske Mt Ten Ham et al.
Pleun Schonewille et al.
Relapse remains the leading cause of failure after allogeneic stem cell transplantation (allo-SCT) for hematologic malignancies. Donor lymphocyte infusion (DLI), the infusion of lymphocytes from the original stem cell donor, was introduced ...
All shades of gray in the mediastinum: do we have bright ideas about how to diagnose and treat mediastinal gray zone lymphoma in the era of targeted agents? [0.03%]
有关纵隔灰区淋巴瘤诊断和治疗的“灰色”观念？我们在靶向药物时代能否一探究竟？
Clémentine Sarkozy,Alexandra Traverse-Glehen
Clémentine Sarkozy
Mediastinal gray zone lymphoma (MGZL) is defined in the international World Health Organization classification as a B-cell lymphoma with overlapping clinical, morphological, immunophenotypic, and molecular features between primary mediastin...